Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Fingolimod, chemically known as fingolimod phosphate or Gilenya, is a first-in-class oral sphingosine 1-phosphate (S1P) receptor modulator developed primarily for the treatment of relapsing forms of multiple sclerosis (MS). Its molecular formula is C24H30NO2P, and it is uniquely identified by the CAS registry number 856179-35-6. Originally synthesized as an immunomodulatory agent derived from myriocin, a natural product isolated from the fungus *Isaria sinclairii*, fingolimod represents a significant breakthrough in neurology and autoimmune disease management.
Upon oral administration, fingolimod undergoes rapid phosphorylation by sphingosine kinase 2 to form its active metabolite, fingolimod phosphate. This active form binds with high affinity to S1P receptors, specifically subtypes 1, 3, 4, and 5, located on lymphocytes. By sequestering these receptors, the drug prevents lymphocytes from egressing from lymph nodes into the bloodstream. Consequently, this mechanism effectively reduces the number of circulating autoreactive T-cells that would otherwise cross the blood-brain barrier and attack the myelin sheath in patients with MS. Unlike traditional immunosuppressants that broadly dampen the immune system, fingolimod offers a more targeted approach by trapping immune cells within secondary lymphoid organs.
Clinically, fingolimod has been approved by major regulatory agencies, including the US FDA and the European Medicines Agency, for treating highly active relapsing-remitting multiple sclerosis in adults. It has demonstrated efficacy in reducing annualized relapse rates, minimizing MRI lesion activity, and delaying disability progression. Beyond MS, ongoing research explores its potential utility in other inflammatory conditions such as uveitis, psoriasis, and certain renal diseases, although these applications remain investigational. Despite its therapeutic benefits, fingolimod requires careful monitoring due to potential adverse effects, including bradycardia upon initiation, macular edema, and increased susceptibility to infections. The development of fingolimod marked a paradigm shift in MS therapy, offering patients a convenient oral alternative to injectable biologics while providing robust disease-modifying capabilities.